Leukemia & lymphomaHumansMultiple MyelomaMaleFemaleAntineoplastic Combined Chemotherapy Protocols
Subcutaneous daratumumab plus carfilzomib and dexamethasone (D-Kd) versus carfilzomib and dexamethasone (Kd) in patients with relapsed/refractory multiple myeloma who received previous daratumumab treatment: LYNX study.
Nizar J Bahlis, Jeffrey Zonder, Lionel Karlin, Torben Plesner, Laura Paris, Tomasz Wrobel, Vania Hungria, Britta Besemer, Edvan Crusoe, Trine Silkjaer, Aurore Perrot, Philippe Moreau, Ka Lung Wu, Sosana Delimpasi, Meletios A Dimopoulos
Published: 202510.1080/10428194.2025.2561117
Abstract
Daratumumab-based regimens demonstrate clinical efficacy in relapsed/refractory multiple myeloma (RRMM). As more patients receive frontline daratumumab-based therapy, evaluation of daratumumab retreatment is needed. In the phase 2 LYNX study (Clinica…
Preview only. Read the full abstract at the source